For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for NATERA INC (Common Stock) – ticker 45E (NTRA) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -41 (−100…+100 Quality+Value blend) · Quality -12 · Value -69 · Sentiment 71 (timing only, not weighted)
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
NATERA INC (Common Stock) – ticker 45E
NTRA NASDAQNatera Inc. is a diagnostics company specializing in advanced genetic testing services for patients, clinicians, and healthcare systems. The company focuses on analyzing cell-free DNA to support clinical decision-making across several key areas of medicine. Natera’s portfolio includes non-invasive prenatal tests that screen for chromosomal abnormalities, carrier screening tests for inherited genetic conditions, and products supporting in vitro fertilization through pre-implantation genetic testing. It also offers testing for products of conception and non-invasive paternity testing, addressing needs in reproductive health and family planning. Beyond prenatal and fertility applications, Natera provides tests used in oncology and organ health, where circulating DNA analysis can inform monitoring and risk assessment. Headquartered in Austin, Texas, Natera operates primarily through a laboratory services model, working with obstetric, fertility, oncology, and specialty practices, as well as hospital systems and reference laboratories. The company plays a prominent role in the genetic diagnostics market by providing high-complexity tests designed to integrate into routine clinical workflows and support personalized care decisions.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -1.52
Total Equity: $1.71B
Shares: 136,721,000
Total Debt: $80.32M
Cash: $1.08B
EBITDA: -$268.15M
Total Debt: $80.32M
Cash: $1.08B
Revenue: $2.31B
Shares: 136,721,000
Revenue: $2.31B
Revenue: $2.31B
Revenue: $2.31B
Total Equity: $1.71B
Tax Rate: 22.4%
Equity: $1.71B
Total Debt: $80.32M
Cash: $1.08B
Current Liabilities: $441.23M
Long-Term Debt: $0.00
Total Debt: $80.32M
Total Equity: $1.71B
Shares: 136,721,000
Shares: 136,721,000
CapEx: -$106.19M
Shares: 136,721,000
Stock Price: $324.84
Net Income: -$208.16M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 20, 2026 8:31pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $625.5M | $820.2M | $1.1B | $1.7B | $2.3B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | — | — | — | — | — |
| Operating Income | -$468.2M | -$541.0M | -$446.2M | -$222.3M | -$309.9M |
| Net Income | -$471.7M | -$547.8M | -$434.8M | -$190.4M | -$208.2M |
| EBITDA | -$456.9M | -$524.3M | -$422.1M | -$191.3M | -$268.1M |
| EPS | $-5.21 | $-5.57 | $-3.78 | $-1.53 | $-1.52 |
| EPS (Diluted) | $-5.21 | $-5.57 | $-3.78 | $-1.53 | $-1.52 |
Balance Sheet (Annual)
Last updated: Aug 20, 2026 8:07pm (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $466.1M | $642.1M | $945.6M | — | $1.1B |
| Total Current Assets | $1.2B | $1.3B | $1.4B | — | $1.5B |
| Total Assets | $1.4B | $1.4B | $1.7B | — | $2.4B |
| Current Liabilities | $310.5M | $307.3M | $344.0M | — | $441.2M |
| Long-Term Debt | $281.7M | $282.9M | — | — | — |
| Total Liabilities | $688.7M | $676.4M | $465.3M | — | $685.9M |
| Total Equity | $705.7M | $765.3M | $1.2B | — | $1.7B |
| Retained Earnings | -$1.9B | -$2.4B | -$2.6B | — | -$2.8B |
Cash Flow (Annual)
Last updated: Aug 20, 2026 8:31pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$335.2M | -$431.5M | -$247.0M | $135.7M | $215.3M |
| Capital Expenditure | -$41.0M | -$47.7M | -$39.2M | -$66.4M | -$106.2M |
| Free Cash Flow | -$376.3M | -$479.2M | -$286.2M | $69.2M | $109.1M |
| Acquisitions (net) | -$8.6M | — | — | — | -$16.0M |
| Net Debt Issued / (Repaid) | -$79.2M | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | — | — | — | — | — |
Growth Trends (YoY %)
Last updated: Aug 20, 2026 8:31pm (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +31.1% | +32.0% | +56.7% | +35.9% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -15.6% | +17.5% | +50.2% | -39.4% |
| Net Income Growth | -16.1% | +20.6% | +56.2% | -9.3% |
| EBITDA Growth | -14.8% | +19.5% | +54.7% | -40.2% |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-20 23:11Even the bull case prices 57% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 100%. Caveat: the company is pre-profit — scenario margins are a glide-path assumption, not a track record.
| Case | Growth | Margin | Fair value | vs price ($324.84) |
|---|---|---|---|---|
| Bull — recovery | +74% | 17.3% | $139.63 | -57% |
| Base — stabilizes | +50% | 15.0% | $65.49 | -80% |
| Bear — keeps slipping | +25% | 12.8% | $27.23 | -92% |
| Stress — last quarter repeats | +40% | -7.1% | $0.00 | -100% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-20 23:08The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Starting with the raw tape: revenue went from $439.8M in Q3'24 to $752.8M in Q2'26 — that's 71% growth over seven quarters, and the sequential prints ($546→$592→$665→$696→$753) show acceleration, not the "decelerating" trend the revenue confidence tag suggests. FY25 revenue of $2.31B vs FY24's $1.70B is 36% YoY, and if you annualize the Q2'26 run-rate you're at roughly $3.0B, implying 2026 growth could still print 30%+. Operating losses narrowed from -$541M (2022) to -$310M (2025) while revenue nearly tripled — operating leverage is real. FCF flipped positive to $109M in 2025 with $1.08B cash against $80M debt. This is not a company at existential risk; it's a company at valuation risk.
Where I part ways with the synthesis: the "priced for perfection" framing is directionally right but the thesis score of -8 (near neutral) and the market-forces "unavailable" leave the actual math underspecified. At $46.8B on $2.31B FY25 revenue, P/S is ~20x; on my $3.0B run-rate estimate, forward P/S is ~15.5x. For a diagnostics platform growing 35%+ with an inflecting FCF profile and $1B net cash, 15x forward sales is rich but not deranged — Veeva, Guidewire, and other "platform" comps have sustained 15-20x through similar phases. The bear case that "MRD develops slower than priced" is the correct bear case, but Signatera volume growth is what's actually driving the sequential acceleration you see in the tape; the market isn't dreaming, it's extrapolating an observable ramp. The narrative model calling this "unanchored" overstates it — there's a $753M quarterly print anchoring things.
That said, the contrarian critique the models under-weight: Q1'26 and Q2'26 net income turned sharply more negative (-$85M and -$67M) after Q4'25's $47M profit — the profit "inflection" was a head-fake, likely driven by one-time items or reimbursement catch-ups. Cash burn per share is masked because share count keeps rising (equity funded the growth — total equity is $1.71B against cumulative losses well north of that). Insider activity is 100% sales in early August 2026 with zero opens; even small, these are unanimous. Gross margin is missing from the tile entirely — a red flag for a diagnostics company where mix (Signatera vs Panorama vs Prospera) determines everything. And "revenue confidence decelerating" from the momentum module contradicts my read of the sequentials; someone's wrong and I'd want to see the underlying calc before trusting either. Finally, the FCF quality tag ("Poor") deserves weight: $215M OCF minus $106M capex gives $109M FCF, but on $46.8B market cap that's a 0.23% FCF yield — you're paying 430x FCF, which is where the "priced for perfection" critique actually bites hardest.
Net: I partially agree with the synthesis's caution but think the framing is too bearish on trajectory and too bullish on their own precision. Fair value on 12x forward sales (still premium, but achievable for a 30%+ grower with improving margins) = ~$36B, or ~$250/share — roughly 23% downside from $324.84. On a bull scenario where Signatera hits $1.5B run-rate by 2027 and gross margins expand to 65%, you can justify current price, but you need both. The asymmetry is unattractive at $325: capped upside near $400 barring a beat-and-raise, downside to $220-250 on any Q3'26 disappointment. The insider selling cluster on Aug 7-10, 2026 is a soft "sell the strength" tell from people who see the internal numbers. I'd wait for the next print or a pullback to sub-$260 before committing capital — not a short, but not a buy here.
GPT Reading
What jumps out first is that the business is real and scaling fast, but the stock is priced as if the hard part is already over. Revenue has gone from $625.5M in 2021 to $2.31B in 2025, and the most recent two quarters annualize to roughly $2.9B-$3.0B of sales, with Q2 2026 revenue of $752.8M up 37.7% from $546.6M a year earlier. That is exceptional growth at this size. The income statement is also improving in a directional sense: net losses narrowed from -$547.8M in 2022 to -$208.2M in 2025, and the last four quarters together are much closer to breakeven than the annual figures imply. Just as important, this is not a balance-sheet survival story. With $1.08B of cash against only $80.3M of debt, plus $215.3M of operating cash flow and $109.1M of free cash flow in 2025, Natera has crossed from “fund me” to “self-fund” financially. That deserves a premium.
But the premium here is extreme. At a $46.82B market cap and about $45.8B enterprise value net of cash, investors are paying roughly 16x a $2.9B run rate, or over 20x 2025 revenue. For a diagnostics company that is still losing money quarter after quarter, that multiple leaves almost no room for reimbursement hiccups, volume mix issues, or plain old margin disappointment. The quarterly pattern matters: Natera posted one profitable quarter in Q4 2025 with $47.3M of net income on $665.5M of revenue, then immediately reverted to losses of -$85.1M and -$67.0M in the next two quarters despite revenue stepping up to $696.6M and $752.8M. That tells me operating leverage is not yet durable. If the model were truly snapping into a software-like margin structure, I would expect profitability to hold as revenue rises. Instead, the company is still proving that each incremental revenue dollar can translate into sustained earnings rather than just a narrower loss.
The valuation therefore requires not just continued high growth, but a very specific shape of future growth: revenue likely has to compound toward many billions more while margins inflect dramatically from negative low double digits today to something much richer. The raw numbers do not yet prove that second leg. 2025 operating loss was still -$309.9M on $2.31B of sales, a -13.4% operating margin, actually worse in absolute dollars than 2024’s -$222.3M despite 36% more revenue. Free cash flow helps, but I would not over-credit it when capex was still $106.2M and cash flow quality is flagged as weak; working capital and non-cash add-backs can flatter a business before the P&L catches up. In other words, this is a great growth company, but at $325 the market is capitalizing it like a future category winner with clean reimbursement, limited competition, and eventual premium margins. That is a heroic underwriting standard in diagnostics.
The best argument against this bearishness is straightforward: few companies show this combination of 35%-45% growth, improving losses, positive operating cash flow, positive free cash flow, and a fortress balance sheet. If a company is on the verge of inflecting from lab-scale inefficiency to platform economics, traditional valuation can look absurdly expensive right before the earnings ramp. A bull would point to the move from $1.08B revenue in 2023 to $2.31B in 2025, the shift from deeply negative cash burn to over $100M of FCF, and the fact that Q2 2026 net margin improved to -8.9% from -18.5% a year earlier. They would say the single profitable quarter was not a fluke but an early sign, and that once volumes scale a bit more, today’s 16x-20x revenue can compress quickly on forward numbers. That is possible. I weigh it differently because the market cap already anticipates that exact path; I do not get paid for merely acknowledging that Natera could become great when the stock already prices greatness.
What would change my mind is evidence that profitability is becoming repeatable, not episodic. If Natera can put up two to three consecutive quarters with revenue still above 30% year-over-year and positive net income or at least clearly positive operating income, then the current valuation would look less speculative because the margin structure would finally be visible. I would also reconsider if annual free cash flow moved materially higher from $109.1M toward, say, $400M+ without slowing growth, because then the “cash flow quality” concern would fade and the premium multiple would have a firmer base. Until then, I think the business deserves admiration and the stock deserves skepticism.
Grok Reading
Natera’s numbers describe a genuine scale-up that has not yet earned its valuation. Revenue compounded from $625M in 2021 to $2.31B in 2025 and is still printing mid-to-high-30s year-over-year growth into mid-2026 ($752.8M in the June quarter versus $546.6M a year earlier). That trajectory, plus the 2025 inflection to $215M of operating cash flow and $109M of free cash flow on a fortress balance sheet ($1.08B cash, $80M debt, current ratio 3.4), is the clean part of the story. The dirty part is that GAAP remains firmly red: 2025 operating loss of $310M, net loss of $208M, and the two most recent quarters back in the hole at –$85M and –$67M after a single profitable blip in Q4 2025. At $46.8B of equity value the stock trades at roughly 19–20× trailing sales and 20× EV/revenue while operating margin sits at –13% and ROIC at –34%. That multiple only clears if Signatera and the broader cfDNA platform deliver multi-billion oncology and transplant franchises at software-like incremental margins within a handful of years. Growth is also decelerating (CAGR 46% versus recent YoY ~36%, flagged as decelerating), and every recent insider print is a sale. The quantitative models that slap a “pre-profit growth” label and then still underwrite 20× sales are leaning on narrative, not on the income statement in front of them.
The market is therefore paying today for a $8–12B revenue, 60%+ gross-margin diagnostics platform that does not yet exist. Reimbursement expansion, MRD standard-of-care adoption across tumor types, and durable pricing power against larger labs are all embedded as base case, not upside. A single quarter of black ink does not constitute operating leverage; the subsequent two quarters of renewed losses show how thin the path still is. Cash-flow quality is labeled poor for a reason—FCF turned positive while the P&L did not, and capex remains material. At $325 the asymmetry is poor: execution has to be near-perfect for five-plus years just to grow into the current price.
The strongest counter-argument is straightforward and numerate. Very few diagnostics businesses have ever layered 35%+ growth on a $2B+ base while flipping to positive free cash flow and carrying net cash. If Signatera’s clinical-validation and reimbursement cadence continues, volume operating leverage could drive the P&L to breakeven faster than the trailing loss run-rate implies, and a 12–15× sales multiple on a larger base would still support or expand today’s capitalization. The balance sheet removes near-term dilution risk, so the company can keep investing through any reimbursement noise. A bull who believes MRD becomes routine monitoring across solid tumors can defend $47B as the entry price to a category-defining asset rather than a peak multiple. I weigh that case as real but incomplete: it still requires the oncology TAM to materialize on the optimistic timetable, competition to stay polite, and margins to expand dramatically from today’s –9% to –13% net levels. None of those are visible in the current quarterly series; they are assumptions layered on top of it.
I would flip to neutral or constructive only on sustained GAAP profitability (two or more consecutive quarters of positive operating income with expanding margins), a clear re-acceleration of revenue growth back above 40% on the larger base, or explicit multi-tumor reimbursement wins that de-risk the Signatera path to several billion of revenue. Absent those, the stock is priced for an outcome the financials have not yet begun to deliver.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Natera is executing a genuine commercial ramp: revenue compounded from $625M in 2021 to $2.31B in 2025 (roughly 39% CAGR), operating margin improved from -74.8% to -13.4%, and FCF flipped from -$376M to +$109M. Liquidity is comfortable with $1.08B cash and $995.8M net cash, and Altman Z of 40.4 signals no solvency risk. The trajectory is that of a category leader in molecular diagnostics (Signatera, Panorama, Horizon) scaling into operating leverage.
Verify before trusting this (7)
- Actual gross margin trajectory by segment (Signatera vs Panorama vs Horizon) from 10-K
- Signatera reimbursement coverage and average selling price trends
- Customer/payer concentration risk
- Ongoing patent litigation exposure (Ravgen, CareDx, etc.)
- 10b5-1 plan status for insider sales - are they programmatic or discretionary?
- Path and timeline to GAAP profitability per management guidance
- SBC vesting schedule and dilution trajectory going forward
The e2e synthesis reads as pricing in a $10B+ oncology diagnostics franchise that doesn't yet exist, and the market cap ($46.8B) confirms it - this is roughly 20x plus of a company that still posts ~$200M GAAP losses and only $109M FCF (which is arithmetically dwarfed by $355M of stock-based comp). Even crediting the reproductive-health cash engine and Signatera's real momentum, the deserved value has to lean on TAM expansion, reimbursement wins, and margin scale that are years out and contested by bear-case reimbursement/competitive risk.
Verify before trusting this (5)
- Signatera volume growth and ASP trajectory in latest 10-Q
- Medicare coverage decisions on MRD and organ transplant assays
- Gross margin trajectory and whether operating leverage is finally materializing
- SBC as % of revenue and forward dilution guidance
- Cash burn vs FCF - is the gap closing or widening
The non-fundamental pressure on NTRA is decisively positive right now. The active narrative is a strong, moderately durable 'platform-monopoly' story around cell-free DNA becoming standard of care - exactly the kind of story that gets bid in a neutral-to-risk-on tape. That narrative just got fresh oxygen: a 21% single-day surge on the Q2 beat and raise on Aug 7 (record Signatera volumes, guide raised), plus a high-profile Druckenmiller top-holding article on Aug 20 flagging the name as up 37% YTD. That is the kind of press coverage that pulls generalist and momentum flows in. The macro tape is a mild net positive (regime +17, VIX 16) and not the dominant force here - but with beta 1.51 and a story-driven, pre-profit profile, NTRA would be the FIRST name to get hit if the tape rolled over. It hasn't. Instead the tape is calm enough to let the narrative do the work. Momentum is strong_positive (46% CAGR, 3y +31pp), which reflexively feeds the story and attracts trend capital. The only real offset is that recent 35.9% trails the 46% long-term pace - a hint the parabolic phase may be maturing - and the bear frame (pre-profit, $47B cap, reimbursement risk) is always one bad print or sector rotation from reasserting. But TODAY, none of those cracks are active. Net: heavy tailwind.
Verify before trusting this (4)
- Whether VIX creeps back above 20 or the S&P breaks recent lows - high-beta story stocks like NTRA get sold first in a regime flip
- Any Signatera reimbursement or clinical-utility setback that would puncture the platform narrative
- Sell-side target revisions post-Q2 - are analysts chasing the beat higher or already balking at valuation
- Signs the Druckenmiller/generalist inflow narrative is fading (position trims in next 13F cycle)
The world is moving toward cell-free DNA as a routine surveillance tool rather than a specialty test: recurrence monitoring, transplant rejection, and prenatal screening are all shifting from episodic tissue/imaging workflows to serial blood draws. That shift expands testing frequency per patient, which is structurally favorable to whoever owns the clinical evidence base and the lab throughput. Macro is neutral (10y 4.71, normal-ish curve) and largely irrelevant to test volumes, which are clinically rather than discretionarily driven. The binding external variable is not demand but payer policy — the pace at which coverage follows guidelines determines how much of a growing clinical need converts to recognized revenue.
When we made this prediction on Aug 21, 2026, NTRA was $326.89. We expect it to be $305.00 by Feb 2027, and we consider it great value under $240.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 21, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.